WickedDesk Weekly #004: Rotation Against the Wind

Three stories in five sessions. Monday closed the Dow at a record 53,056. Tuesday and Wednesday the Iran escalation pushed Brent above 78 dollars and the regime score down to 41. Thursday semiconductors bought the market back. The regime score sits at 64 intraday on Friday, yellow, with 0.25R as the risk unit.

The real story runs under the surface: capital is leaving the hot baskets of recent months and accumulating healthcare and cybersecurity. 48 of the 133 stocks in the leader screen are biotech. Semiconductors defends rank 1 while losing one-month momentum. That tension defines next week's preparation.

The plan stays selective. Breadth at 37 of 100 does not carry broad breakouts, A-grade setups with traction come first, and Tuesday brings the catalyst day with CPI and JPMorgan.

Monday: Dow record close 53,055.91 (+0.29%), S&P 500 7,537.43 (+0.72%), Nasdaq 26,121.16 (+1.12%), technology bought broadly. Tuesday: Iran oil license revoked, Brent above 76 dollars, semiconductors in distribution, MU -4.7%, SMH -3%, Nasdaq -1.16%. Wednesday: the agreement declared over, Brent above 78 dollars, Dow -1.1%, the 10-year yield at 4.60%, the highest since May. Thursday: fresh airstrikes, and the market shook them off. S&P 500 +0.81% to 7,543.64, Nasdaq +1.30% to 26,206.89, SMH +2.5%, oil down.

One paragraph sets the scene, one sentence compresses it: the market digested the macro shock in two days, but only with narrow leadership.

The regime score tells the same path in numbers: 49 on the prior Thursday, 41 on Wednesday, 64 intraday on Friday. Friday's close is still open and will face these numbers in next issue's follow-up check.

The chronicle does not matter, the plan changes do. Three events shift the preparation: the oil shock puts rate and margin pressure back on the agenda, Tuesday's semiconductor distribution demands tighter selection inside the strongest basket, and Delta's sold-off beat shows record numbers do not get paid against rising fuel costs.

The Dow record was built on a narrow base. On the prior Thursday only 25.1% of stocks advanced; Friday intraday it is 30.4%. 52.3% of the universe trades above the 50-day line, and the breadth pillar of the regime score stands at 37 of 100.

At the same time the leadership pillar reads 76 of 100 with 1,232 stocks in strong momentum. Together that is not a contradiction but the signature of this phase: narrow, strong leadership above a sluggish majority. In practice: breakouts only where group and stock deliver at the same time.

Short version: the index prints records, breadth prints work.

The worry is on the table: is the Nasdaq overextended after the run and due for consolidation first? The data answers more precisely than the gut. QQQ trades 15.9% above its 50-week line. That is the top quartile of the past five years, but not a record: in July 2023 the distance reached 26%.

On the daily timeframe the stretch is already worked off. QQQ sits just 1.3% above the 50-day line and 0.4% above the 21-day line, 3.4% below a high that is 24 sessions old. The index has been consolidating sideways for over a month while headlines talk records. The digestion many are calling for is already underway.

Consequence for preparation: the index is not the question, its leadership is. As long as the 50-day line holds, the sideways phase is base building. A daily close below it would be the first measurable deterioration, and index exposure gets reduced then.

The theme ranking shows the week more clearly than any index. Cybersecurity jumps from rank 12 to 3, biotech from 13 to 6, artificial intelligence from 14 to 7, data center from 15 to 9. On the losing side: clean energy from 5 to 8 at -15.2% on the month, bitcoin miners from 2 to 4 at -15.5%, consistent with bitcoin sliding to roughly 62,500 dollars.

Genomics holds rank 2 with +24.3% on the month, the strongest monthly print of any top basket. Healthcare accumulation is a multi-week pattern, not a single session.

The leaders of the risers: FTNT, OKTA, PANW in cybersecurity, MRNA, ARWR, BEAM in biotech, DELL, MU, ARM in AI. Trading the rotation starts with these lists.

The industry ranking confirms the theme picture. Semiconductors defends rank 1, but with -8.3% average one-month momentum across members. Biotech & pharma climbs from 9 to 5 at +12.4% on the month. Software works its way from 17 to 12. At the bottom, nuclear & uranium (32 to 36) and consumer electronics (29 to 34) confirm the distribution in spring's story baskets.

Semiconductors is the strongest basket in the ranking and the most fragile of the week. Tuesday brought broad distribution, MU -4.7%, SMH -3%. Thursday bought everything back, SMH +2.5%, SNDK +7.6%. Between those two sessions sits the question this issue names openly: is the basket building a top or a base?

The facts under the hood: the semis theme loses 3.8% on the month, the industry averages -8.3%, while rank 1 holds. SMH trades 1.7% below its 21-day line and 9.5% below a high that is twelve sessions old. Relative strength without fresh momentum is the classic signature of a decision zone. The desk rule for it: tops are processes, bottoms are events. A top would be weeks of work, not one red Tuesday.

Both outcomes now have measurable marks. The top thesis wins if SMH loses its 50-day line on a closing basis and the leaders (SIMO, PENG, CRDO) stop printing new highs. It is annulled if new highs arrive on relative volume above 1. The SK Hynix listing at 149 dollars brings fresh memory capital into the basket and is next week's first test.

The quietest story of the week is the biggest one. The leader screen (RS at least 90, at most 15% below the high, three months at least +20%, ADR at least 3%, dollar volume at least 15 million) holds 133 stocks. 48 of them are biotechnology, plus medical care, diagnostics and healthcare plans. No other block fields even half of that.

Genomics leads the monthly theme list at +24.3%, biotech follows at +15.1%. The quality reaches into the tight ranges: RVMD (RS 99, 2.3% below the high), CRNX (RS 98, at the high), HUM and CNC from healthcare plans, ILMN in diagnostics. This is accumulation over weeks, not a sector squeeze.

Consequence: healthcare goes on next week's first watch list, focused on bases near highs rather than already extended names.

The biggest rank jump of the week: cybersecurity from 12 to 3. The basket combines what is scarce in this regime, defensive demand and growth charts near highs. FTNT sits at RS 94 just 4.1% below its high with a 4.2% ADR, OKTA at RS 94 in exactly the same zone, PANW and RPD follow inside the basket.

The geopolitical week delivers the catalyst for free: escalation raises security budgets regardless of the rate cycle. Unlike semis, momentum here rises with the rank, +11.0% on the month.

Work order: run FTNT and OKTA as pivotal point candidates, entries only at tight marks, no buying into the extended weekly candle.

When the strongest basket tips into consolidation, the decisive question is not whether but how long. SMH's own five-year history gives a clear distribution: there are two kinds of semiconductor bases, with almost nothing in between.

The routine digestions: September 2021 (about 1 month to a new high), summer 2023 (3.1 months), spring 2024 (2.3 months), autumn 2025 (0.8 months), February 2026 (1.2 months). The cycle breaks: November 2021 to July 2023 at 18.7 months, and July 2024 to July 2025 at 11.5 months. Each measured from the high through a correction deeper than 8% to the next new high.

The difference between the two kinds was historically never the chart alone but the macro behind it: 2022 was the rate cycle turning, 2024 the AI capacity question. Which is exactly why the current answer hangs on Tuesday. If CPI stays tame and the hike remains speculation, history argues for the short kind, one to three months of sideways work. If CPI confirms the hike debate, the 18-month path of 2022 is the honest reference. Months of consolidation are a realistic scenario, not alarmism, and the marks from the semis dossier stand unchanged.

SPCX has been listed since June 12, the largest IPO of the year. The debut close was 160.95 dollars, the peak three days later 225.64, a 40% premium over the first close. Since then the stock has worked its way lower: currently 148.53 dollars, below the round 150 mark and barely above the IPO low of 145.20. Trading volume has visibly ebbed since the debut.

The structure is unambiguous: the first IPO base resolved downward, not upward. A fresh IPO below its debut price and below the psychological mark is not a long setup, however big the story. Story and structure are two separate tests, and SPCX currently passes only the first.

For the watch list that means: below 145.20 the range is open to the downside and the name stays untouchable. Only a reclaim of the 150 to 161 zone (the debut close) on a closing basis would repair the base and start a new study. Until then SPCX is a dated observation, not a candidate. Data as of July 10 intraday; the first Friday close below 150 would confirm the break.

DAL delivered premarket on Friday: EPS 1.56 versus 1.51 expected, record revenue of 17.67 billion, +14% year over year, full-year guidance reinstated at 6.50 to 7.50 dollars EPS. The market's answer: -3.7% intraday, from 91.68 to 88.28 dollars in a 87.25 to 90.50 range.

The read belongs in this season's playbook: in a week with Brent above 78 dollars, airline records get netted against the fuel bill. A beat is not enough when the macro thread runs against it. The implied move was 6.9%, the reaction stayed below it, panic looks different.

The broad season opens Tuesday: JPMorgan at 7:00 ET, CPI at 8:30 ET the same morning. How bank numbers and inflation data get processed together defines the regime of the coming weeks. Open expectation, follow-up in issue 005.

The week's control list: leader-screen names at most 5% below their high with moderate ADR. The sector color of the list stands out, cybersecurity and healthcare field almost everything. Tight ranges near highs are the raw form of the pivotal point; the next breakout generation is built here.

Three candidates from the screen, one per story of the week: AI hardware at the high, healthcare accumulation, the semis decision zone. All three are study objects with marks, not recommendations. The full chart sits behind every ticker click.

PENG is the high-pressure candidate. RS 99, closing at the high (the 52-week high dates from the last session), three months +259%, ADR 12.4%, average dollar volume 280 million. Price sits 45.7% above the 50-day line and 22.7% above the 21-day line.

The numbers say two things: demand is real and institutional, and the distance to every support line is wide. The stock's own history has seen bigger stretches (up to 107% above the 50-day line), but this is not the clean entry. Study order: wait for the first tight flag above the 21-day line. The strength thesis is void below the 21-day line on a closing basis.

CRNX carries the healthcare thesis with the calmest structure in the basket. RS 98, closing practically at the 52-week high (0.2% away, the high is two days old), three months +109%, a moderate 4.5% ADR, dollar volume 258 million.

The stretch is the counterpoint to PENG: 111% above the 50-day line after a trend thrust, the third highest reading of its own five-year history. This is no longer a fresh breakout, but it is intact accumulation. Study order: treat consolidation above the 21-day line as a new base; a drop below last week's breakout level breaks the thesis.

SIMO is the semis test in portfolio format. RS 99, three months +162%, ADR 8.3%, dollar volume 366 million, currently 8.7% below a twelve-session-old high, 17% above the 50-day line and 6.5% above the 21-day line.

The stock draws the basket question in miniature: pullback inside an intact stage-2 structure, or the first building block of a top. The memory backdrop (SK Hynix listing, Thursday's MU recovery) argues for the first read. Study order: if the 21-day line holds and volume turns to the buy side, the pullback is the opportunity. A close below the 50-day line ends the study.

Three candidates reached the screen and were cut anyway. The reasons are part of the process, not footnotes.

The week's frame in four numbers: Brent above 78 dollars after two escalation steps, the 10-year yield up to 4.60% and back to 4.56%, the dollar index at 101 with a weekly gain, gold above 4,100 dollars. The market prices roughly a 70% probability of a September rate hike, the real break with spring's easing fantasy.

Bitcoin slid to 62,200 to 62,900 dollars and delivered the explanation for miner distribution along the way. The VIX oscillated between 17 and 18, elevated but without a panic spike.

For the process this means: rate and oil sensitive setups carry an extra burden of proof until CPI and the FOMC (July 29) clarify the picture.

The regime dictates the size: at yellow with warning breadth the risk unit stays at 0.25R, A-grade setups with own traction only. New positions need group, stock and mark at the same time; two out of three is not enough.

Second rule of this issue: every open expectation gets its follow-up check. Delta's closing price, the SK Hynix debut, Friday's index closes, all three will stand next to their actual values in issue 005. Forecasts that are never checked teach nothing.

Tuesday, July 14, is the densest date of the new week: JPMorgan opens the Q2 season at 7:00 ET, the June CPI follows at 8:30 ET the same morning. A hot CPI into a live rate-hike debate would stress test the 4.60% mark on the 10-year and everything priced off multiples.

The week's control points, in order: first, SMH against its 50-day line as the semis decision. Second, the healthcare control list (RVMD, CRNX, HUM, CNC, ILMN) for base breakouts. Third, FTNT and OKTA at their marks. Fourth, the regime score: above 60 with better breadth opens the book, below 50 closes it again.

Open expectations from this issue: Friday closes for all indices, Delta's closing price, the SK Hynix debut, the weekly VIX close. Follow-up in 005.